In Q3-FY23, revenue and NPAT were VND 467 billion (+12% YoY) and VND 70 billion (+25% YoY), respectively. In which, revenue from self-produced pharmaceuticals accounted for 95% of total net revenue. The two main sales channels, ETC and OTC, reported revenues of VND 192 billion (+15% YoY) and VND 252 billion (+5% YoY), respectively. Forecast for 2023F, revenue and NPAT will be VND 1,980 billion (+20% YoY) and VND 317 billion (+36% YoY), with an EPS of 3,847 VND. For 2024F, revenue and NPAT are...
In May 2023, net revenue and PBT were VND 142 billion (+48% YoY) and VND 33 billion (+81% YoY), respectively. Accumulated 5M2023, net revenue and PBT were VND 774 billion (+50% YoY) and VND 165 billion (+61% YoY), respectively completing 44% and 47% of the plan for 2023 and 37% and 38% of our forecast. For 2023F, net revenue and NPATMI were VND 2,110 billion (+28% YoY) and VND 346 billion (+48% YoY), of which the ETC and OTC channels revenue reached VND 975 billion (+70% YoY) and VND 1,064 b...
In Q1/2023, IMP's net revenue and PBT were VND 479 billion (+53% YoY) and VND 99 billion (+50% YoY), completing 27.4% and 28.3% of the 2023 target. In which, The ETC and OTC channel revenue were VND 178 billion (+241% YoY) and VND 297 billion (+15% YoY), respectively. Q1/2023 revenue and PBT are both completing 23% of our latest 2023 forecast. IMP has set a plan for net revenue and PBT of VND 1,750 billion and VND 350 billion respectively, increasing by 7% and 20% compared to 2022. IMP's grow...
A director at Imexpharm Corporation bought 139,900 shares at 0.000VND and the significance rating of the trade was 57/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years...
In Q3-2022, IMP recorded net revenue and PBT of VND 418 billion (+63% YoY) and VND 72 billion (+89% YoY), respectively. Accumulated 9M2022, net revenue and PBT reached VND 1,087 billion (+25% YoY) and VND 197 billion (+27% YoY), completing 75% and 72% of the annual plan. Net revenue and PBT accumulated 9M2022 completed 70% and 71% of our forecast, respectively. IMP 4 factory will help IMP become the first domestic company to participate in competitive bidding with foreign manufacturing compan...
· Accumulated 8M2022, revenue and PBT reached VND 954 billion (+20.2% YoY) and VND 171.4 billion (+18.3% YoY), respectively completing 65.8% and 62.3% of the annual plan. The pharmacy sales channel (OTC) continued to maintain strong growth as it reached 41.7%, while the hospital channel (ETC) grew -2.1% YoY but showed some recovery. · The IMP4 factory was officially announced by the Ministry of Health to meet the EU – GMP standards in 09/2022. This is the factory with th...
Full Article at IIR has reaffirmed its Recommended rating for PIA after undertaking a review post the appointment of a new Portfolio Manager, Harding Loevner. The full report can be found on the IIR website. On 26 July 2021, Pengana International Equities Limited (PIA) announced a fully franked dividend of 1.35 cents per share for the June quarter. This represents an 8% increase on the March quarter dividend and takes the total dividends declared for FY21 of 5.1 cents per share, fully franked....
Although Covid-19 hit IMP's core business, the company executed effective measures to cut SG&A expenses and maintained a high net income growth rate in Q3. Due to higher orders and IMP’s attempts to cut expenses, we expect the company will record the highest quarterly net income ever in Q4 20 and fulfill the annual pre-tax profit target of VND260bn. Owing to its large potential from EU-GMP factories and favourable policies, IMP 's prospect in 2021 is bright. We will update our 2021 forecast ...
For 2020, we believe that IMP will meet its net income target due to strong growth in its ETC sales and its attempt to cut SG&A expenses. In 2021, we expect that it will maintain high growth in revenue as its new EU-GMP factory runs commercially. We recommend Accumulate with a target price of VND52,500, plus cash dividend of VND1,500 — a total return of 12%, compared to the closing price on 28 August 28 2020. H1 20: Decent performance during tough times In 6M 20, IMP maintained high growth ....
Circular 15 (effective from October 2019) reclassifies drug tiers for ETC generic drugs bidding, replacing Circular 11 issued in 2016. This is considered beneficial for domestic pharmaceutical companies, especially those with high standard manufacturing facilities. Some changes in the new circular: (1) Tightening technical standards for each drug tier, and (2) preference for domestically produced drugs. According to the new circular, in order to bid for Tier 2, production ...
​We have decided to change our recommendation from NEUTRAL to BUY for IMP. Considering the growth prospects of IMP, we believe that a valuation of VND80,000/share, equivalent to P/E of 21x is appropriate for 2018. Compared to the closing price of VND63,000/share on September 15, the target price, coupled with a stable dividend of VND1,800/share, yields a total expected return of 30%.It is not a bargain-hunting opportunity as its stock is trading at P/E of 23x for 2017. IMP has a growth stock s...
Ford Equity International Research Reports cover 60 countries with over 30,000 stocks traded on international exchanges. A proprietary quantitative system compares each company to its peers on proven measures of business value, growth characteristics, and investor behavior. Ford's three recommendation ratings buy, hold and sell, represent each stock’s return potential relative to its own country market.. The rating reports which are generated each week, include the fundamental details behind...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.